Distinct Contributions of Vaccine-Induced Immunoglobulin G1 (IgG1) and IgG2a Antibodies to Protective Immunity against Influenza
Top Cited Papers
- 1 September 2006
- journal article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 13 (9) , 981-990
- https://doi.org/10.1128/cvi.00156-06
Abstract
Vaccination represents the most effective form of protection against influenza infection. While neutralizing antibodies are typically measured as a correlate of vaccine-induced protective immunity against influenza, nonneutralizing antibodies may contribute to protection or amelioration of disease. The goal of this study was to dissect the individual contributions of the immunoglobulin G1 (IgG1) and IgG2a antibody isotypes to vaccine-induced immunity against influenza virus. To accomplish this, we utilized an influenza vaccine regimen that selectively enhanced IgG1 or IgG2a antibodies by using either DNA or viral replicon particle (VRP) vectors expressing influenza virus hemagglutinin (HA) (HA-DNA or HA-VRP, respectively). After HA-DNA vaccination, neutralizing antibodies were detected by both in vitro (microneutralization) and in vivo (lung viral titer) methods and were associated with increased IgG1 expression by enzyme-linked immunosorbent assay (ELISA). Vaccination with HA-VRP did not strongly stimulate either neutralizing or IgG1 antibodies but did induce IgG2a antibodies. Expression of IgG2a antibodies in this context correlated with clearance of virus and increased protection against lethal influenza challenge. Increased induction of both antibody isotypes as measured by ELISA was a better correlate for vaccine efficacy than neutralization alone. This study details separate but important roles for both IgG1 and IgG2a expression in vaccination against influenza and argues for the development of vaccine regimens that stimulate and measure expression of both antibody isotypes.Keywords
This publication has 90 references indexed in Scilit:
- Comparison of Immune Responses to Gonococcal PorB Delivered as Outer Membrane Vesicles, Recombinant Protein, or Venezuelan Equine Encephalitis Virus Replicon ParticlesInfection and Immunity, 2005
- Avian Influenza A (H5N1) Infection in HumansNew England Journal of Medicine, 2005
- Cross‐Reactivity to Highly Pathogenic Avian Influenza H5N1 Viruses after Vaccination with Nonadjuvanted and MF59‐Adjuvanted Influenza A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming StrategyThe Journal of Infectious Diseases, 2005
- A DNA transfection system for generation of influenza A virus from eight plasmidsProceedings of the National Academy of Sciences, 2000
- Correlates of Immune Protection Induced by Live, Attenuated, Cold‐Adapted, Trivalent, Intranasal Influenza Virus VaccineThe Journal of Infectious Diseases, 2000
- Intranasal Interleukin‐12 is a Powerful Adjuvant for Protective Mucosal ImmunityThe Journal of Infectious Diseases, 1999
- Th2 Responses to Inactivated Influenza Virus Can Be Converted to Th1 Responses and Facilitate Recovery from Heterosubtypic Virus InfectionThe Journal of Infectious Diseases, 1999
- FcR γ chain deletion results in pleiotrophic effector cell defectsCell, 1994
- The Immunoglobulin G Subclass Responses of Mice to Influenza A Virus: the Effect of Mouse Strain, and the Neutralizing Abilities of Individual Protein A-purified Subclass AntibodiesJournal of General Virology, 1989
- Activation of mouse complement by monoclonal mouse antibodiesEuropean Journal of Immunology, 1981